Changes In Serum Adiponectin Levels Research Articles

Effects of Hydroxycitric Acid Supplementation on Body Composition, Obesity Indices, Appetite, Leptin, and Adiponectin of Women with NAFLD on a Calorie-Restricted Diet.

This trial assessed the effects of a calorie-restricted diet (CRD) with hydroxycitric acid (HCA) supplementation on appetite-regulating hormones, obesity indices, body composition, and appetite in women with nonalcoholic fatty liver disease (NAFLD). This study was carried out on 44 overweight/obese women with NAFLD. The patients were randomly assigned into two groups, namely, "Intervention group" (receiving individual CRD plus HCA tablets per day) and "Control group" (receiving only CRD) for eight weeks. Obesity indices, body composition, appetite status, and serum levels of leptin and adiponectin were assessed before and after the intervention. Forty patients completed the trial. At the end of the trial, although significant reductions were found in most of the studied obesity indices in the intervention group, there was only a significant decrease in waist circumference and waist-to-height ratio in the control group. Fat mass and muscle mass significantly decreased in the intervention group (p=0.044 and p=0.024, respectively), and the reduction in visceral fat in the intervention group was significantly greater than that in the control group (-0.49 kg vs -0.37 kg, p=0.024). Intra- and intergroup differences in serum leptin and adiponectin levels and their ratios before and after the trial were not significant. We found a negative and marginally significant correlation between percent of changes in serum adiponectin level and percent of changes in visceral adipose tissue (VAT) (r = -0.429, p=0.067) and BMI (r = -0.440, p=0.059) as well as an inverse relationship between percent of changes in leptin/adiponectin with VAT (r = -0.724, p < 0.001) in the intervention group. HCA plus weight loss diet could significantly reduce visceral adipose tissue without any significant changes in serum leptin and adiponectin levels.

Associations between rs2241766 and rs3774261 polymorphisms in ADIPOQ gene and atopic dermatitis

Atopic dermatitis (AD) is a common skin condition that affects both children and adults. Adipokines have been shown to play a role in the pathogenesis of AD. In the current study, the association between adiponectin gene (ADIPOQ) polymorphisms and AD was investigated. In addition, changes in serum adiponectin levels in AD patients were examined. Restriction fragment length polymorphism-PCR technique was used to genotype ADIPOQ SNPs. The ELISA assay was used to measure serum Adiponectin levels. A total of 324 participants (162 AD and 162 healthy controls) were included in the study. The frequency of the GG genotype of rs3774261 was higher in the AD group (44.5%) than in the control group (32.7%, P<0.05). Regarding the rs2241766 SNP, the frequency of the GG genotype was higher in the AD group (10.5%) than in the control group (3.1%), while the frequency of the TT genotype was lower (P<0.001) in the AD group (35.8%) than the control group (57.4%). Moreover, the GG haplotype of rs3774261 and rs2241766 significantly increased the risk of AD by about 2-fold (P<0.05). Finally, serum adiponectin levels were lower in the AD group than in the control group (P<0.05). These results indicate an association of the rs2241766 and rs3774261 SNPs with the risk of developing AD among the population examined.

Analysis of changes on adiponectin levels and abdominal obesity after smoking cessation.

PurposeThe blood levels of Adiponectin, anti-inflammatory and anti-arteriosclerotic adipocytokine, decrease due to smoking and obesity. Cigarette smokers are generally known to gain weight after smoking cessation (SC). Nevertheless, precise changes in serum adiponectin levels after SC and specific effects of abdominal obesity on those changes remain unknown. The objective of this study was to elucidate the changes in serum adiponectin levels after SC and the effects of abdominal obesity on those changes.MethodsIn 86 patients (56 males and 30 females) who had successfully quit smoking, serum adiponectin levels were measured using an enzyme-linked immunosorbent assay at baseline and 1 year after beginning SC.ResultsBody mass index and waist circumference (WC) were significantly increased 1 year after beginning SC. Adiponectin levels, however, did not change after SC. Using the median ΔWC (+2.8%) as the cutoff point, patients were then divided into two groups. The percent change in adiponectin levels from baseline to 1 year was significantly greater in the ΔWC < median group (−1.1%) than in the ΔWC ≥ median group (+8.1%) (p = 0.011).ConclusionsDespite weight gain and increased abdominal obesity, serum adiponectin levels did not decrease after SC. Therefore, the beneficial effect of SC may eliminate the adverse effects of subsequent weight gain. Conversely, patients with less abdominal obesity had increased adiponectin levels 1 year after SC. Therefore, in such patients, the beneficial effect of SC on adiponectin levels is apparent.

Changes in serum adiponectin levels in children with severe sepsis and its clinical significance

Objective To study the changes in serum adiponectin level in children with severe sepsis, and to explore its clinical significance. Methods A prospective study was conducted, and 39 cases of critically ill children with severe sepsis and 47 cases of sepsis were enrolled into the Pediatric Intensive Care Unit(PICU), Children′s Hospital of Nanjing Medical University from July 2012 to July 2014.Thirty cases of critically ill children without sepsis were enrolled as a control group.The plasma adiponectin, procalcitonin (PCT), and C-reactive protein(CRP) were determined with enzyme linked immunosorbent assay (ELISA) within 24 hours after PICU admission.The pediatric critical illness score (PCIS) was recorded. Results Among severe sepsis group, sepsis group and control group, there was no statistical significance in body temperature, heart rate, body mass index, PCIS, white blood cell count, platelet count, bilirubin, creatinine, pH value and activated partial thromboplastin time(APTT) (all P>0.05). Plasma adiponectin in the severe sepsis group[(0.102±0.041) mg/L] significantly decreased compared with that in the sepsis group[(0.125±0.046) mg/L] and the control group[(0.147±0.047) mg/L](F=8.456, P=0.000). The level of CRP in the severe sepsis group[(60.68±59.43) mg/L] significantly increased compared with that in the sepsis group[(52.76±26.67) mg/L] and the control group[(33.89±6.87) mg/L] (F=17.416, P=0.000). There was a statistical significance in PCT level in the severe sepsis group, the sepsis group and the control group (χ2=27.269, P=0.000). Further comparison showed that there was a significant difference in PCT level between the severe sepsis group and the sepsis group (Z=-4.679, P=0.000), which was also statistically significant between the severe sepsis group and the control group (Z=-4.244, P=0.000); there was no significant difference between the sepsis group and the control group (Z=-0.340, P=0.733). Negative correlation was found between plasma adiponectin and CRP (r=-0.219, P=0.042), PCT (r=-0.303, P=0.005). The correlation between plasma adiponectin and PCIS was positively correlated (r=0.332, P=0.002). Conclusions Plasma adiponectin decreased in severe sepsis children and was significantly associated with the severity of the disease.Detection of plasma adiponectin levels in children with sepsis has an important clinical significance in evaluating the severity of sepsis.Plasma adiponectin is negatively correlated with CRP and PCT, and plays a role in diagnosis of infection. Key words: Adiponectin; Severe sepsis; Critical illness; Pediatric critical illness score

Acute exercise improves serum adiponectin not leptin in sedentary adult obese men

Leptin and adiponectin, adipose tissue secreted cytokines, play key role inobesity and cardiovascular disease. Although the physiopathological mechanisms underlying these associations are largely unknown. Venous blood samples were obtained before and after an acute bout of moderate cycling test in eighty non‐trained adult obese men (BMI: 33.54 ± 3.43 kg/m2) that participated in this study by accidentally. Blood samples were used for measuring serum leptin and adiponectin. No significant differences were found in serum leptin by cycling exercise with compared to baseline (P ≥ 0.05). But, serum adiponectin levels were significantly increased in response to acute exercise when compared with baseline levels (P &lt; 0.05). Based on these data, we can say, although inflammation cytokines such as leptin does not affect by acute exercise for short time, but it seems that this exercise can increase anti‐inflamatory cytokines as adiponectin in obese subjects. The findings of this study indicate the fact that in response to short‐term exercise, changes in serum adiponectin levels are independent of the leptin response.

Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?

IntroductionProgressive fibrosis in systemic sclerosis (SSc) is linked to aberrant transforming growth factor beta (TGF-beta) signaling. Peroxisome proliferator-activated receptor gamma (PPAR-gamma) blocks fibrogenic TGF-beta responses in vitro and in vivo. Reduced expression and function of PPAR-gamma in patients with SSc may contribute to progression of fibrosis. Here we evaluated the levels of adiponectin, a sensitive and specific index of PPAR-gamma activity, as a potential fibrogenic biomarker in SSc.MethodsAdiponectin levels were determined in the sera of 129 patients with SSc and 86 healthy controls, and serial determinations were performed in 27 patients. Levels of adiponectin mRNA in skin biopsies from SSc patients were assessed in an expression profiling microarray dataset. Regulation of adiponectin gene expression in explanted human subcutaneous preadipocytes and fibroblasts was examined by real-time quantitative PCR.ResultsPatients with diffuse cutaneous SSc had reduced serum adiponectin levels. A significant inverse correlation between adiponectin levels and the modified Rodnan skin score was observed. In longitudinal studies changes in serum adiponectin levels were inversely correlated with changes in skin fibrosis. Skin biopsies from a subset of SSc patients showed reduced adiponectin mRNA expression which was inversely correlated with the skin score. An agonist ligand of PPAR-gamma potently induced adiponectin expression in explanted mesenchymal cells in vitro.ConclusionsLevels of adiponectin, reflecting PPAR-gamma activity, are correlated with skin fibrosis and might have potential utility as a biomarker in SSc.

Angiopoietin-like protein 2 sensitively responds to weight reduction induced by lifestyle intervention on overweight Japanese men.

Objective:Overexpression of Angiopoietin-like protein 2 (Angptl2) in obese adipose tissues promotes adipose tissue inflammation and its-related metabolic abnormalities. In a comparative study with adiponectin, we investigated whether alterations in serum Angptl2 concentrations reflect the effect of lifestyle intervention on weight loss and improved metabolic parameters in overweight subjects.Methods:A total of 154 Japanese men (age, 40.9±5.1 years; body mass index, 26.9±3.6 kg m−2; abdominal circumference, 94.1±8.9 cm) underwent a 3-month lifestyle intervention and underwent follow-up for 3 months thereafter.Results:Decreased serum Angptl2 levels, but not increased serum adiponectin levels, were immediately apparent at the end of 3-month lifestyle intervention. Angptl2 levels continued to decrease for 3 months in parallel with body weight loss and improvement in metabolic indicators. In subjects showing ⩾6% weight reduction, markedly reduced Angptl2 levels were detected at the end of 3-month intervention, whereas increased adiponectin levels were detected 3 months after the end of intervention. Multivariate analysis revealed changes in serum Angptl2 levels associated with changes in triglycerides (TGs), aspartate aminotransferase and alanine aminotransferase. In contrast, changes in serum adiponectin levels were associated with altered high-density lipoprotein cholesterol (HDL-C) and fasting plasma glucose levels.Conclusion:A 3-month lifestyle intervention promoted weight reduction and improved glucose and lipid metabolism, an effect maintained 3 months later. Notably, our findings indicate that decreased Angptl2 levels are a good indicator of reduced visceral fat and metabolic improvement at early stages of lifestyle intervention. Thus, Angptl2 reflects adiposity and might be a key protein to regulate inflammation and TG metabolism, whereas adiponectin levels could reflect improved glucose and HDL-C metabolism.

Changes in Serum Adiponectin Levels from Birth to Term-Equivalent Age Are Associated with Postnatal Weight Gain in Preterm Infants

Background: Adiponectin, one of the adipocytokines, is postulated to play a key role in fetal growth, probably enhancing the growth-promoting effect of insulin through insulin-sensitizing action. Objectives and Methods: To examine how different intrauterine or postnatal growth patterns relate to adiponectin secretion, we measured serum adiponectin concentrations in 30 appropriate-for-gestational-age (AGA) and 19 small-for-gestational-age (SGA) preterm infants on the first day of life and at term-equivalent age. Results: The serum levels of adiponectin increased significantly in all preterm infants from birth to term-equivalent age. The adiponectin levels at term-equivalent age were significantly higher in the AGA than in the SGA group [mean (SD) 40.4 (12.3) vs. 28.4 (10.4) µg/ml; p < 0.01] after adjustment for gestational age or term-equivalent body weight. The increase in adiponectin levels from birth to term-equivalent age was significantly higher in the AGA than in the SGA group, and was positively correlated with the weight gain rate (g/kg/day) in the combined groups (r = 0.37, p < 0.01). A multiple regression analysis with the adiponectin increase from birth to term-equivalent age as the dependent variable for all the subjects revealed that only weight gain rate was independently associated with the adiponectin increase. Conclusions: Our results suggest that the change in serum adiponectin levels may reflect postnatal growth from birth to term-equivalent age in preterm infants.

Study of adiponectin in chronic liver disease and cholestasis

Adiponectin is an adipocytokine suggested to have a hepatoprotective effect. To date, little information is available in the literature regarding changes in serum adiponectin levels in cirrhosis and cholestasis and the associated metabolic disturbances. In order to elucidate the role of adiponectin in chronic liver disease our aim was to determine serum adiponectin in patients with different grades of cirrhosis and cholestasis and to correlate it with markers of liver injury, inflammation and cholestasis. We also aimed to correlate adiponectin with markers of metabolic syndrome such as body mass index and insulin resistance. Forty patients with cirrhosis; 30 patients with cirrhosis and cholestasis; and 20 matched controls were studied. They were subjected to clinical assessment, laboratory investigations: serum bilirubin, ALT, AST, alkaline phosphatase, GGT, albumin, C-reactive protein, prothrombin activity, fasting blood sugar, insulin. HOMA index was calculated. Abdominal ultrasonography and upper GI endoscopy were performed. Adiponectin was elevated in patients with cirrhosis and cirrhosis/cholestasis and was significantly higher in Child A and B. Adiponectin showed correlation with liver cell injury, marker of inflammation, synthetic liver function and markers of cholestasis. Adiponectin did not correlate with complications of cirrhosis as ascites and esophageal varices nor did it correlate with BMI or HOMA. Adiponectin is elevated in cirrhosis and shows correlation with degree of hepatocellular injury and cholestasis. Finally, adiponectin levels in cirrhosis do not correlate with parameters of body composition or metabolism but exclusively with reduced liver function.

Decrease in Adiponectin Levels Correlates to Growth Response in Growth Hormone-Treated Children

Background/Aims: Adiponectin is secreted by adipose tissue and circulates in human plasma at high levels. Decreased adiponectin levels are associated with insulin resistance and obesity. The aim of this study was to investigate whether changes in serum adiponectin levels are related to the growth response, insulin levels and insulin resistance during growth hormone (GH) treatment. Methods: The study included 94 short prepubertal children (19 girls and 75 boys). The mean age at the start of daily GH injections was 9.04 ± 2.38 years. Adiponectin levels in serum were measured using an ELISA. Results: At baseline, adiponectin correlated with the first-year growth response (r = 0.26, p = 0.012). Adiponectin decreased significantly after 1 week, 3 months and 1 year from 14.5 ± 5.71 to 13.1 ± 5.22 (p < 0.0001), 10.3 ± 4.82 (p < 0.0001) and 12.5 ± 5.34 μg/ml (p < 0.0001), respectively. There were significant correlations between the first-year growth response and the decrease in adiponectin levels after 3 months and 1 year (r = –0.38, p < 0.0001 and r = –0.47, p < 0.0001, respectively). No correlations between adiponectin, insulin and the homeostasis model assessment of insulin resistance were seen. Conclusions: GH treatment in prepubertal children decreases serum adiponectin levels, and the decrease is correlated to the growth response. No correlations between adiponectin and insulin levels or insulin resistance were found.

Serum Concentrations of Adiponectin in Patients with Hyperthyroidism before and after Control of Thyroid Function

Thyroid hormone affects adipocyte function, which in turn influences lipid and carbohydrate metabolism. Adiponectin is one of the adipocytokines that regulates lipid and carbohydrate metabolism. The aim of our study was to evaluate circulating levels of adiponectin in patients with thyroid dysfunction before and after normalization of thyroid function with appropriate medication. One hundred and twenty patients with hyperthyroidism were recruited at the time of diagnosis. Measurements of free T4 (FT4), thyroid-stimulating hormone (TSH), thyrotropin binding inhibitor immunoglobulin (TBII), adiponectin, fasting blood glucose, fasting serum insulin, lipid profile, and body mass index (BMI) were taken before and after 6 months of medical treatment, at which point all patients were in a euthyroid state. Any change in BMI was strongly correlated with changes in serum-adiponectin levels (r = -0.789, p<0.001). Any change in serum FT4 was also correlated with changes in BMI and serum adiponectin levels (r = -0.254, p = 0.05 and r = 0.501, p = 0.029 respectively). After controlling for BMI changes, we found correlation also between serum FT4 and adiponectin (r = 0.29, p = 0.005). Multivariate-regression analysis still revealed BMI to be a statistically strong predictor for serum-adiponectin level (p<0.001). However, that analysis also revealed thyroid function level as another predictor (p = 0.029). Although BMI is the best predictor of adiponectin, that thyroid hormone might influence circulating levels of adiponectin.

Study of Serum Adiponectin in Chronic Liver Disease and Cholestasis

Purpose: Adiponectin is suggested to have a hepatoprotective effect. To date, there is minimal information available in the literature regarding changes in serum adiponectin levels in cirrhosis and cholestasis and the associated metabolic disturbances. Therefore, our aim was to elucidate the role of adiponectin in chronic liver disease and to correlate adiponectin level with liver functions &markers of the metabolic syndrome as body mass index and insulin resistance in these patients. Methods: 40 patients with different grades of cirrhosis, 30 patients with cirrhosis & cholestasis and 20 matched controls were studied. They were subjected to clinical assessment, BMI and Child score calculations, analysis of ALT, AST, alkaline phosphatase, GGT, C-reactive protein, HOMA index, adiponectin, abdominal ultrasonography & upper GI endoscopy. Results: Adiponectin was significantly higher in patients than controls (cirrhosis: 15.1 ± 12.14 μg/ml vs 4.7 ± 4.48 μg/ml, P < 0.05 and cirrhosis/cholestasis: 21.28 ± 10.2 μg/ml vs 4.7 ± 4.48 μg/ml, P= 0.001). Adiponectin correlated with bilirubin (r = 0.369, P < 0.05), ALT (r = 0.283, P < 0.05), AST (r = 0.367, P < 0.05), albumin (r =− 0.287, P < 0.05), prothrombin (r = 0.278, P= 0.053), ALP (r = 0.394, P < 0.005), GGT (r = 0.298, P < 0.05), CRP (r = 0.406, P < 0.05). Adiponectin didnot correlate with presence of ascites or esophageal varices nor did it correlate with BMI or HOMA index. Conclusion: adiponectin is elevated in cirrhosis and correlates with degree of hepatocellular injury and cholestasis. It could serve as a novel marker indicating cholestasis in liver cirrhosis. Adiponectin in cirrhosis does not correlate with parameters of body composition or metabolism but exclusively with reduced liver function.